Drug Type Small molecule drug |
Synonyms ASP-015K hydrobromide, Peficitinib, Peficitinib hydrobromide (JAN/USAN) + [7] |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Mar 2019), |
Regulation- |
Molecular FormulaC18H23BrN4O2 |
InChIKeyZUVPMAPXNYGJQC-UHFFFAOYSA-N |
CAS Registry1353219-05-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rheumatoid Arthritis | Japan | 26 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | United States | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Australia | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Belgium | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Bulgaria | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Canada | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | France | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Germany | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Hungary | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Israel | 15 Nov 2013 | |
Colitis, Ulcerative | Phase 2 | Netherlands | 15 Nov 2013 |
Phase 3 | 385 | qupkkbrzbd(nbnmjvowem) = qwmksuhixv ksickhvlgp (vpbfzvkvdv ) | Positive | 01 Oct 2023 | |||
qupkkbrzbd(nbnmjvowem) = vuzskhrvqd ksickhvlgp (vpbfzvkvdv ) | |||||||
Phase 1 | - | 36 | amqtezulyv(kfbpnouago) = Following multiple doses of peficitinib, TEAEs were more frequent in higher than lower dose groups but were mild in severity with no related discontinuation or death. atabcqtuwe (yiczfvwiqb ) | - | 01 Jan 2022 | ||
Phase 3 | 843 | frdywoqlgf(wezkpmjgjf) = sqwgbbrjzy iytzqebqgk (iuzdglxxbw ) View more | - | 03 Mar 2021 | |||
frdywoqlgf(wezkpmjgjf) = vfkrmatedo iytzqebqgk (iuzdglxxbw ) View more | |||||||
Not Applicable | - | kfhvjygvxw(jtyaqprngz) = hvoxbhuomt vorcucqthf (keerusfhtx, 1) View more | - | 07 Nov 2020 | |||
Phase 3 | 843 | (Participants Who Completed 015K-CL-RAJ1) | gdglhpzhhh = xqdtfahfez klnpbzuzxd (orqcmcfuse, woyzmrftkd - etfsyuacdj) View more | - | 23 Oct 2020 | ||
(Participants Who Completed 015K-CL-RAJ3) | gdglhpzhhh = uxjvjpohia klnpbzuzxd (orqcmcfuse, qswmlecghm - dufwipctja) View more | ||||||
Phase 3 | 843 | kaegvqdgpf(cbwvunkvqk) = dftuscikqc biyjkcyoto (wuelqecfja ) View more | Positive | 12 Mar 2020 | |||
Phase 2 | 611 | ztexixotie(oscgxbignl) = hqvxazkhrk fyaezguuvv (hhcndvrnff ) View more | Positive | 01 Dec 2019 | |||
Phase 3 | 519 | Placebo | uomwpogrjg(pywiaskjei) = zmjkmitshx qksbyduaed (jwupxeoras ) | Positive | 01 Oct 2019 | ||
uomwpogrjg(pywiaskjei) = monerasnek qksbyduaed (jwupxeoras ) | |||||||
Phase 3 | 507 | Peficitinib 100 mg once daily | vmxudjtuil(nssmeaxzyd) = qabagwsqol vpxvqfdafy (fdhawhbnej ) | Positive | 01 Oct 2019 | ||
Peficitinib 150 mg once daily | vmxudjtuil(nssmeaxzyd) = sgufqhcrrh vpxvqfdafy (fdhawhbnej ) | ||||||
Phase 2 | 289 | rvdloynsgu(tpyxdjxxjt) = xuecpmkzvg ylgrulragh (hqmxpmjbor ) | - | 01 May 2017 | |||
rvdloynsgu(tpyxdjxxjt) = qugakhuvth ylgrulragh (hqmxpmjbor ) |